Issues & Perspectives

Platz Named Editor-in-Chief of Cancer Epidemiology, Biomarkers & Prevention

Platz Named Editor-in-Chief of Cancer Epidemiology, Biomarkers & Prevention

Posted by  | Issues & Perspectives, Research

A national publication on cancer causes, prevention, detection and survivorship will have a Johns Hopkins cancer epidemiologist at the helm for 2019. Elizabeth Platz, M.P.H., Sc.D, is the co-leader for cancer prevention and control at the Johns Hopkins Kimmel Cancer Center. She was named as editor-in-chief of Cancer Epidemiology, Biomarkers & Prevention (CEBP), one of(...)

Moving for Melanoma of Delaware Supports Melanoma Research at Johns Hopkins

Moving for Melanoma of Delaware Supports Melanoma Research at Johns Hopkins

Posted by  | Giving Back, Issues & Perspectives

Members of the Johns Hopkins Melanoma Program participated in an annual 5K walk/run event and received funds raised by the event during a visit in February. The 5K event in Wilmington, Delaware, and sponsored by Moving for Melanoma of Delaware for the past 11 years raises money for melanoma research, community education and support patients and(...)

Pancreatic Cancer Matters: Right Treatment at the Right Time

Pancreatic Cancer Matters: Right Treatment at the Right Time

Posted by  | Issues & Perspectives, pancreatic cancer, precision medicine, Research, treatment

Our collaborative team of scientists, physicians and allied health workers at the Johns Hopkins Kimmel Cancer Center specialize in translating science learned in the laboratory into exceptional clinical care. The Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care is a world leader in the diagnosis and management of pancreatic cancer, leading all(...)

The Future of Pancreatic Cancer Treatments

The Future of Pancreatic Cancer Treatments

Posted by  | Issues & Perspectives, pancreatic cancer, Prevention/Screening, Research, treatment

Just eight percent of people with pancreatic cancer live for five years after their diagnosis. Why is this cancer so deadly and where are advances in treatment headed? Elizabeth Jaffee, M.D., deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, describes explains in a 2018 interview on WYPR. http://www.wypr.org/post/why-pancreatic-cancer-so-deadly

Immune Checkpoint Inhibitor Therapy Guideline Continues to Draw Readers

Immune Checkpoint Inhibitor Therapy Guideline Continues to Draw Readers

Posted by  | Issues & Perspectives

A guideline on guide the clinical practice of managing adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy continues to draw readers nearly a year after its publication. The document’s development, led by Julie Brahmer, M.D., co-director of the upper aerodigestive department in the Bloomberg~Kimmel Institute for Cancer Immunotherapy and a professor of(...)

Jaffee looks to the future of checkpoint immunotherapy for cancer treatment

Jaffee looks to the future of checkpoint immunotherapy for cancer treatment

Posted by  | Issues & Perspectives, precision medicine, Prevention/Screening, treatment

Combinations strategies involving checkpoint immunotherapies were approved as first-line options in two cancer types and showed promise in clinical trials for several hard-to-treat cancers. Important advances were also made with respect to immune-related biomarkers, cellular immunotherapies, and personalized vaccines. Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, is focusing her research(...)

Three Minutes with Oncologist Michael Carducci

Three Minutes with Oncologist Michael Carducci

Posted by  | caregiving, Issues & Perspectives, palliative care, Research

Michael Carducci, M.D., is the associate cancer center director for clinical research within the Johns Hopkins Kimmel Cancer Center and the regional research director for the Greater Washington, D.C., area for the Kimmel Cancer Center. In his many years as an oncologist, Carducci has expertise in various types of cancer including bladder, kidney, prostate and(...)

Benefits of Immunotherapy in Metastatic Non-Small Cell Lung Cancer

Posted by  | Issues & Perspectives, Research, Survivorship

Julie Brahmer, M.D., is an active clinical leader in the treatment of lung cancer and mesothelioma. As the director of the Thoracic Oncology Program and professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, her research and clinical practice focuses on the development of new therapies for the treatment and prevention(...)

Washington Post Cancer Summit: A Silent Epidemic: The rise of HPV-related cancers

Posted by  | Issues & Perspectives, Prevention/Screening, Research

Akila Viswanathan, M.D., executive vice chair of Johns Hopkins Radiation Oncology and Molecular Radiation Sciences, was part of a panel discussion on the rise of HPV-related cancers. The panel was just one section of the Washington Post Cancer Summit. Viswanathan was joined by other experts in taking look at rising HPV-related cancer rates in the(...)

Why Do People Get Cancer?

Posted by  | Issues & Perspectives

Adult cancers tend to be a little different from childhood cancers, and trying to explain the disease to a young person adds to the separation. Dr. Donald Small, director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center, said cancer in children is rare, and most are treatable. But trying to explain a cancer(...)